Steven Zivko Pavletic

Elevated plasma anandamide levels in sclerotic chronic graft-versus-host disease highlight the endocannabinoid system as a potential therapeutic target

Sencer Göklemez, Steven Zivko Pavletic, Hyoyoung Choo-Wosoba, Filip Pirsl et autres

us, at (code pays fourni par la source)

Chronic GVHD Consortium CATCH Study: Incidence, initial presentation and risk factors for chronic GVHD development

Joseph A. Pidala, Betty K. Hamilton, George Liwei Chen, Lynn Onstad et autres

The incidence of chronic graft-versus-host disease (GVHD) is declining but up to 30% of survivors are still diagnosed with chronic GVHD. We conducted a prospective, multi-center, observational study to understand the incidence and earliest presenting signs and symptoms of chronic graft vs. …

us (code pays fourni par la source)

A Comparative Analysis of Skin Responses per 2014 NIH Response Criteria and Modified 2025 NIH Skin Task Force Response Criteria in Patients With Sclerotic Chronic Graft-Versus-Host Disease

Amila Kapetanović, Rania Hishmeh, Anita Stokes, Edward W. Cowen et autres

us (code pays fourni par la source)

Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force

Alina Markova, Stephanie J. Lee, Badri G. Modi, Emily Baumrin et autres

Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study

Noa G. Holtzman, Annie Im, Lauren M. Curtis, Eduard Schulz et autres

ABSTRACT: Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality among transplant survivors. Therapeutic targeting of the Janus kinase (JAK)-STAT pathway has proved to be an effective approach for cGVHD; however, toxicities …

us, at (code pays fourni par la source)

Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease

Antonela Lelas, Lana Desnica, Ivan Sabol, Désirée Coen Herak et autres

hr, ba, us (code pays fourni par la source)

Desmosine as a Novel Biomarker Candidate for Pulmonary and Cutaneous Chronic Graft-Versus-Host Disease

Aaron T. Zhao, Filip Pirsl, J V Parkin, Alain Antoine Mina et autres

us, gb (code pays fourni par la source)

Targeting the IL-8 axis in high-risk myelodysplastic syndromes: a clinical experience with antibody blockade combined with decitabine/cedazuridine

Alain Mina, Katherine R. Calvo, Katherine M. McKinnon, Ayush T. Raman et autres

Clinical and laboratory findings are presented from a 64-year-old female with myelodysplastic syndrome and increased blasts-2 (MDS-IB2) from Phase I/II trial evaluating the anti-IL8 antibody, BMS-986253, in combination with oral decitabine/cedazuridine (NCT05148234). Each 28-day cycle included BMS-986253 1200 mg IV on Day …

us (code pays fourni par la source)

Effect of vitamin D replacement on nutritional status and muscle strength in patients after allogeneic stem cell transplantation and chronic graft-versus-host disease

Dina Ljubas Kelecic, Irena Karas, Antonela Lelas, Lana Desnica et autres

hr, us (code pays fourni par la source)

Toward Better and More Effective Clinical Trials for Chronic Graft-Versus-Host Disease.

Daniel Wolff, Corey S. Cutler, Iveta Merćep, T. Jaki et autres

Frequency and Characteristics of Membranous Conjunctivitis after Allogeneic Transplantation.

Aaron T. Zhao, Najla El Jurdi, Chantal Cousineau-Krieger, Susan Vitale et autres

us (code pays fourni par la source)

Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force

Alina Markova, Stephanie J. Lee, Badri G. Modi, Emily Baumrin et autres

The National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) Consensus Project established response criteria that enabled clinical trials and facilitated regulatory approval of multiple therapies. Nonetheless, organ-specific assessments have limitations, particularly for severe sclerotic skin involvement. Cutaneous manifestations occur in approximately …

us, jp, ca, ch (code pays fourni par la source)